Maintenance DFMO Increases Survival in High Risk Neuroblastoma

High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Sholler, Giselle L. Saulnier, Ferguson, William, Bergendahl, Genevieve, Bond, Jeffrey P., Neville, Kathleen, Eslin, Don, Brown, Valerie, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Parikh, Nehal S., Eshun, Francis, Zage, Peter, Rawwas, Jawhar, Sencer, Susan, Pankiewicz, Debra, Quinn, Monique, Rich, Maria, Junewick, Joseph, Kraveka, Jacqueline M.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6160434/
https://ncbi.nlm.nih.gov/pubmed/30262852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-32659-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados